BPC-157 (Body Protection Compound-157) Evidence Grade: A-
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a naturally occurring protective protein found in human gastric juice. It is one of the most extensively studied research peptides, with over 100 preclinical studies documenting its capacity to accelerate healing across tendon, ligament, bone, muscle, gut mucosal, and neurological tissue models. Its unique stability in gastric acid distinguishes it from most peptides, enabling both injectable and oral routes of administration.
The compound operates through pleiotropic mechanisms rather than a single receptor target, modulating the nitric oxide system, growth factor signaling, and inflammatory cascades simultaneously. As of 2026, BPC-157 remains classified as a research compound without approved therapeutic indications, though limited Phase I/II clinical trials have been conducted in inflammatory bowel disease and wound healing contexts.
Table of Contents
Overview
BPC-157, also referred to by its experimental designations PL 14736 and PL-10, is a synthetic pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a larger naturally occurring protein called Body Protection Compound (BPC), which is secreted in human gastric juice and believed to play a role in mucosal protection and repair within the gastrointestinal tract.
Unlike the majority of research peptides that degrade rapidly when exposed to stomach acid and digestive enzymes, BPC-157 exhibits remarkable stability in human gastric juice. This stability has led researchers to investigate both injectable (subcutaneous and intramuscular) and oral routes of administration, making it one of the few peptides viable for oral delivery. The peptide's molecular weight of approximately 1419.53 Da places it in the small peptide category, contributing to its relative stability and tissue penetration.
The research landscape for BPC-157 is dominated by preclinical (animal) studies, with the vast majority conducted by Dr. Predrag Sikiric and colleagues at the University of Zagreb, Croatia. This body of work, spanning from the early 1990s to the present, encompasses over 100 published studies documenting effects across multiple organ systems and injury models. The consistency of results across different tissue types, dosing routes, and experimental conditions has established BPC-157 as one of the most well-characterized research peptides in the preclinical literature [1][2].
Key research endpoints include accelerated healing of tendons, ligaments, and muscles; protection and repair of gastrointestinal mucosa; neuroprotective effects in CNS injury models; and cardioprotective properties in ischemia-reperfusion models. The compound does not appear to have a single identified receptor; instead, it modulates multiple downstream signaling pathways simultaneously, which may account for the breadth of its observed effects. This pleiotropic mechanism has drawn comparisons to other multi-target therapeutic molecules but also complicates the traditional drug development pathway.
Mechanism of Action
BPC-157's mechanism of action is characterized by its engagement of multiple molecular pathways rather than a single receptor-ligand interaction. This polypharmacological profile makes it unusual among research peptides and has generated significant interest in understanding how a single short peptide can exert effects across such diverse tissue types. The following pathways represent the most well-characterized mechanisms identified in the literature.
BPC-157 modulates the nitric oxide system through activation of endothelial nitric oxide synthase (eNOS), promoting vasodilation, angiogenesis, and improved blood flow to damaged tissues. In models of vascular injury and ischemia-reperfusion, the peptide restores NO homeostasis. Its cytoprotective effects in gut anastomosis models are partially dependent on NO pathway integrity, as NOS inhibitors attenuate its protective effects [3]. BPC-157 also counteracts the effects of NOS inhibitors (L-NAME, L-NMMA), suggesting bidirectional regulation of the NO system.
BPC-157 upregulates expression of growth hormone receptor (GHR) in tendon fibroblasts, amplifying local GH signaling even at physiological GH levels. This mechanism is particularly relevant in poorly vascularized tissues such as tendons and ligaments. The peptide also increases VEGF (vascular endothelial growth factor) expression, promoting neovascularization at injury sites [4]. EGF receptor phosphorylation and EGR-1 (Early Growth Response-1) transcription factor activation have been documented, contributing to wound healing and mucosal restitution.
The focal adhesion kinase (FAK) and paxillin signaling cascade is activated by BPC-157, driving cytoskeletal reorganization, cell migration, and adhesion. This pathway is central to wound closure and tissue remodeling. In tendon fibroblast cultures, BPC-157 dose-dependently increases FAK phosphorylation, promoting outgrowth from tendon explants and collagen fiber alignment [5]. This mechanism underlies the peptide's documented acceleration of tendon repair in Achilles tendon transection models.
BPC-157 reduces NF-kB-mediated inflammatory signaling, decreasing pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) in models of systemic inflammation and IBD. This anti-inflammatory action operates alongside its tissue repair properties, allowing simultaneous reduction of inflammation and acceleration of healing. The dual action distinguishes it from purely anti-inflammatory agents, which may impair healing [6].
In the central nervous system, BPC-157 interacts with both dopaminergic and serotonergic neurotransmitter systems. It has been shown to counteract dopamine system dysfunction induced by neuroleptics and amphetamines, and to modulate serotonin receptor activity. These interactions provide the mechanistic basis for observed anxiolytic, antidepressant-like, and neuroprotective effects in rodent behavioral models [7]. The peptide also promotes nerve repair and remyelination in peripheral nerve injury models.
Pathway Integration
The simultaneous engagement of these pathways creates a coordinated tissue repair response: NO-mediated vasodilation increases blood supply to injured tissue; growth factor upregulation stimulates cell proliferation and differentiation; FAK-paxillin activation drives cell migration into wound beds; and NF-kB suppression reduces the inflammatory environment. This integrated response may explain why BPC-157 shows effects across such diverse tissue types rather than being limited to a single organ system.
Research Timeline
The research history of BPC-157 spans over three decades, with the majority of foundational work conducted at the University of Zagreb under Dr. Predrag Sikiric.
Discovery and initial characterization. BPC-157 is first isolated as a fragment of the Body Protection Compound found in human gastric juice. Early studies establish its stability in gastric acid and initial cytoprotective properties in gastric lesion models.
Gastrointestinal research expansion. Sikiric et al. publish studies demonstrating BPC-157's protective effects against NSAID-induced gastric damage, ethanol-induced lesions, and IBD models. Oral administration is validated as effective for GI endpoints.
Musculoskeletal healing studies begin. Research expands to tendon, ligament, and bone healing models. Achilles tendon transection studies in rats show significant acceleration of repair with BPC-157 treatment versus controls.
Mechanism elucidation. Chang et al. (2011) identify the FAK-paxillin pathway as central to BPC-157's tendon repair mechanism. VEGF upregulation and collagen deposition studies provide molecular-level understanding [5].
CNS and brain-gut axis research. Studies document dopaminergic and serotonergic system interactions. The brain-gut axis concept is formalized for BPC-157, linking gastrointestinal and neurological effects [7].
Systematic reviews published. Gwyer et al. (2019) publish the first systematic review of BPC-157's musculoskeletal effects, consolidating evidence across multiple tissue types [8]. Sikiric (2018) publishes a comprehensive review of GI tract activity [1].
Cardiovascular and vascular research. Ischemia-reperfusion studies demonstrate cardioprotective effects. Vascular protective properties are characterized, including promotion of collateral vessel formation [9].
Clinical translation efforts. Limited Phase I/II trials begin in IBD and wound healing contexts. The FDA has not granted IND status for any specific indication as of 2026. Research community interest continues to grow, with increasing attention from sports medicine researchers.
Clinical Evidence Grade: A-
BPC-157's evidence base is overwhelmingly preclinical, with over 100 animal studies and a limited number of human investigations. The A- grade reflects the exceptional breadth and consistency of animal data, tempered by the relative scarcity of controlled human trials.
Human Studies
A limited Phase II trial evaluating oral BPC-157 in patients with ulcerative colitis. Preliminary data suggests improvement in mucosal healing markers and clinical symptom scores. Full results have not been published in peer-reviewed form as of 2026.
Key Preclinical Studies
Comprehensive review covering BPC-157 activity across GI models including NSAID-induced lesions, IBD, esophageal lesions, liver damage, and pancreatic lesions. Documents NO-pathway dependence and EGR-1 upregulation as primary mechanisms of mucosal repair.
Systematic review covering tendon, ligament, and muscle healing models. Found consistent acceleration of collagen synthesis, reduced inflammation, and improved biomechanical strength across multiple animal models. Concluded that BPC-157 represents a promising candidate for clinical investigation.
In vitro and rat Achilles tendon transection model. Dose-dependent enhancement of tendon fibroblast migration, VEGF expression, and FAK/paxillin pathway activation. Histological analysis showed superior collagen fiber alignment in treated animals.
Documents CNS effects including counteraction of dopaminergic dysfunction, anxiolytic properties, and neuroprotective effects. Provides mechanistic framework for the brain-gut axis concept applied to BPC-157.
Demonstrates cardioprotective and vascular protective effects in ischemia-reperfusion models. Reduced infarct size, improved hemodynamic recovery, and promotion of collateral vessel formation. NO-pathway and VEGF-mediated mechanisms confirmed.
Demonstrates BPC-157's promotion of angiogenesis and vasculogenesis. Showed formation of new blood vessels and improved vascular patency in models of vascular injury and thrombosis.
Comprehensive review of BPC-157's effects on peripheral and central nervous system models, including nerve crush injury repair, spinal cord injury models, and neurotoxin protection. Documented promotion of nerve regeneration and functional recovery.
Demonstrated acceleration of liver regeneration following partial hepatectomy. BPC-157 treatment increased hepatocyte proliferation markers and improved functional recovery timelines in rat models.
Evidence Assessment
| Category | Volume | Quality | Consistency |
|---|---|---|---|
| GI Tissue Repair | 30+ studies | High | Very consistent |
| Musculoskeletal Healing | 20+ studies | High | Consistent |
| Neuroprotection | 15+ studies | Moderate-High | Consistent |
| Cardiovascular | 10+ studies | Moderate | Consistent |
| Human Trials | 2-3 trials | Low (limited) | N/A |
Dosing & Administration
The following dosing parameters are derived from preclinical research protocols and limited human trial data. All information is provided for research reference only.
Research Dosing Ranges
| Parameter | Low Range | Standard Range | High Range |
|---|---|---|---|
| Subcutaneous Dose | 200 mcg/day | 250-500 mcg/day | 500-750 mcg/day |
| Intramuscular Dose | 250 mcg/day | 500 mcg/day | 500 mcg 2x/day |
| Oral Dose | 250 mcg/day | 500 mcg/day | 500 mcg 2x/day |
| Cycle Length | 4 weeks | 6-8 weeks | 8-12 weeks |
| Frequency | Once daily | Once daily | Twice daily |
Animal-to-Human Dose Translation
The standard rat dose in preclinical studies is 10 mcg/kg administered intraperitoneally. Using standard allometric scaling (FDA guidance for industry, 2005), the human equivalent dose (HED) is approximately 1.6 mcg/kg. For a 75 kg adult, this translates to approximately 120 mcg/day. Research protocols often use higher doses (250-500 mcg) based on empirical observations and the peptide's favorable safety profile in animal toxicology studies.
Routes of Administration
- Subcutaneous (SubQ): Most common research route. Injection near (not into) the target injury site is preferred in musculoskeletal models. Abdominal injection is standard for systemic endpoints.
- Intramuscular (IM): Used for deeper tissue targets. Similar bioavailability to SubQ but may provide more direct delivery to muscle injuries.
- Oral: Unique among research peptides. Viable due to gastric acid stability. Primarily studied for gastrointestinal endpoints (IBD, leaky gut, mucosal repair). Systemic bioavailability is lower than injectable routes.
- Topical: Limited research data. Some wound healing models apply BPC-157 directly to wound sites, though this is less common.
Reconstitution
Lyophilized BPC-157 is typically supplied in 5 mg or 10 mg vials. Reconstitute with bacteriostatic water (BAC water) using the following guidelines:
| Vial Size | BAC Water | Concentration | 0.1 mL = | 0.2 mL = |
|---|---|---|---|---|
| 5 mg | 2 mL | 2500 mcg/mL | 250 mcg | 500 mcg |
| 5 mg | 2.5 mL | 2000 mcg/mL | 200 mcg | 400 mcg |
| 10 mg | 2 mL | 5000 mcg/mL | 500 mcg | 1000 mcg |
| 10 mg | 5 mL | 2000 mcg/mL | 200 mcg | 400 mcg |
For precise calculations, use the Reconstitution Calculator.
Storage
- Lyophilized (unreconstituted): Store at -20°C for long-term stability. Room temperature storage for short periods (weeks) is generally acceptable.
- Reconstituted: Refrigerate at 2-8°C. Use within 3-4 weeks. Do not freeze reconstituted solution.
- Protect from direct light and repeated freeze-thaw cycles.
Pharmacokinetics
Pharmacokinetic data for BPC-157 is limited and primarily derived from animal models. Human PK studies are scarce, and the following parameters should be interpreted with this limitation in mind.
| Parameter | Value | Source |
|---|---|---|
| Half-Life (estimated) | ~4 hours (SubQ) | Preclinical extrapolation |
| Bioavailability (SubQ) | ~80-90% | Estimated from animal models |
| Bioavailability (Oral) | ~20-40% | Estimated; varies by GI conditions |
| Onset of Action | Minutes to hours (local) | Preclinical |
| Time to Peak Effect | 24-72 hours (tissue repair) | Preclinical histology |
| Duration of Action | 6-12 hours (single dose) | Estimated |
| Metabolism | Proteolytic degradation | Standard peptide metabolism |
| Elimination | Renal (amino acid fragments) | Standard peptide pathway |
Key Pharmacokinetic Notes
- Gastric stability: BPC-157 is uniquely stable in human gastric juice (pH 1-2), resisting degradation by pepsin and hydrochloric acid. This property is central to its viability as an oral peptide and distinguishes it from virtually all other research peptides [1].
- Tissue distribution: Following subcutaneous injection, BPC-157 distributes to local and systemic tissues. Injection near the injury site provides higher local concentrations, which may explain the preference for localized injection in musculoskeletal research.
- No accumulation: Based on the estimated half-life, steady-state conditions are expected to be reached within 24 hours of repeated daily dosing. No evidence of accumulation or tachyphylaxis has been reported in animal studies with chronic administration.
- Dose-response: Preclinical studies generally show dose-dependent effects up to a plateau, with 10 mcg/kg (IP, in rats) identified as the most commonly effective dose. Higher doses do not appear to produce proportionally greater effects.
Side Effects & Safety
BPC-157 has demonstrated a favorable safety profile in preclinical studies, with no reported LD50 (lethal dose) identified even at very high doses in animal toxicology studies. However, human safety data is extremely limited, and the following information should be interpreted in that context.
Reported Effects (Preclinical / Anecdotal)
- Injection site irritation or mild redness (transient)
- Nausea (uncommon, primarily with oral dosing)
- Lightheadedness (transient, likely NO-mediated vasodilation)
- Fatigue or tiredness in initial days of use
- Mild headache (uncommon)
- Warm sensation at injection site
Rare / Theoretical Risks
- Hypotension in individuals sensitive to NO-mediated vasodilation
- Theoretical promotion of pre-existing tumor growth (angiogenesis concern) — no evidence in preclinical studies but a pharmacological consideration
- Unknown long-term effects in humans due to absence of chronic exposure data
- Potential interaction with blood pressure medications (vasodilatory effect)
Important: No LD50 has been identified in animal toxicology studies, which is unusual and suggests a wide therapeutic index. However, this does not constitute evidence of human safety. All use outside approved clinical trials is experimental and carries inherent risk.
Contraindications & Cautions
- Active cancer or history of hormone-sensitive malignancies: The angiogenic properties of BPC-157 (VEGF upregulation, neovascularization) represent a theoretical risk for tumor growth promotion. While no preclinical evidence supports this concern, caution is warranted.
- Pregnancy and breastfeeding: No reproductive toxicology data available. Use should be avoided.
- Anticoagulant therapy: BPC-157's angiogenic and vascular effects may interact with blood-thinning medications. No specific drug interaction studies have been conducted.
- Hypotension or cardiovascular instability: NO-mediated vasodilation may exacerbate pre-existing low blood pressure.
- Children and adolescents: No safety data in pediatric populations.
Toxicology Summary
| Parameter | Finding |
|---|---|
| Acute Toxicity (LD50) | Not identified at maximum tested doses in rodents |
| Chronic Toxicity | No adverse effects in 6-month rat studies |
| Mutagenicity | No mutagenic activity reported (Ames test) |
| Teratogenicity | Not studied |
| Organ Toxicity | No hepatotoxicity, nephrotoxicity, or cardiotoxicity reported |
Stacking & Synergies
BPC-157 is one of the most commonly combined compounds in tissue repair research protocols. Its multi-pathway mechanism creates complementary synergies with compounds that address different aspects of the healing cascade.
| Stack Partner | Synergy Rationale | Common Protocol | Evidence Level |
|---|---|---|---|
| TB-500 (Thymosin Beta-4) | Complementary mechanisms: TB-500 promotes actin-mediated cell migration while BPC-157 drives angiogenesis and growth factor upregulation. Together they address the full tissue repair cascade. | BPC 250-500 mcg/day SubQ + TB-500 2.5 mg 2x/week | High (preclinical) |
| GHK-Cu | GHK-Cu stimulates collagen synthesis and extracellular matrix remodeling. Combined with BPC-157's growth factor activity, this stack supports both new tissue formation and structural maturation. | BPC SubQ daily + GHK-Cu topical/SubQ daily | Moderate (theoretical) |
| Ipamorelin / CJC-1295 | GH secretagogues provide systemic anabolic support (IGF-1 elevation) that enhances BPC-157's local tissue repair effects. Particularly relevant for musculoskeletal injuries. | BPC morning SubQ + Ipamorelin/CJC pre-sleep | Moderate (theoretical) |
| MK-677 (Ibutamoren) | Oral GH secretagogue providing sustained GH/IGF-1 elevation. Combines with BPC-157's GHR upregulation for amplified GH signaling at tissue repair sites. | BPC SubQ daily + MK-677 10-25 mg oral PM | Moderate (theoretical) |
See the BPC-157 compound page for additional stacking recommendations.
Regulatory Status
BPC-157 occupies a complex regulatory position globally. It has not received approval as a therapeutic drug in any jurisdiction as of 2026.
| Jurisdiction | Status | Details |
|---|---|---|
| United States (FDA) | Not approved | No IND application has been publicly granted. Classified as a research chemical. Not included in the FDA's list of approved drugs. The FDA has issued warning letters to companies marketing BPC-157 as a therapeutic product. |
| European Union (EMA) | Not approved | No marketing authorization. Available through research chemical suppliers for investigational use. |
| Australia (TGA) | Not approved / Schedule 4 | Peptides for injection require prescription. BPC-157 may be accessible through compounding pharmacies under TGA Special Access Scheme for investigational use. |
| Canada (Health Canada) | Not approved | No DIN or NPN issued. Research chemical classification. |
| WADA | Not specifically listed (2026) | Not currently named on the WADA Prohibited List, though related peptide classes may be subject to in-competition and out-of-competition testing rules. |
Regulatory Note: BPC-157 is sold as a research chemical and is not approved for human consumption in any jurisdiction. Any use outside of approved clinical trials is at the individual's own risk. Researchers should verify current regulations in their jurisdiction before procuring or using this compound.
Frequently Asked Questions
What is the difference between BPC-157 and BPC-157 arginate?
How long does BPC-157 take to show effects in research models?
Is BPC-157 naturally found in the human body?
Can BPC-157 be used orally or must it be injected?
What is the evidence grade for BPC-157 and why?
References
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2018;24(18):2012-2032. PMID: 29782919
- Sikiric P, et al. "Pentadecapeptide BPC 157 and its effects on a nitric oxide system." J Physiol Pharmacol. 2014;65(5):623-33. PMID: 25371520
- Sikiric P, et al. "The pharmacological properties of the novel peptide BPC 157 (PL-10)." Inflammopharmacology. 1999;7(1):1-14. PMID: 17657443
- Seiwerth S, et al. "BPC 157 and blood vessels." Curr Pharm Des. 2014;20(7):1014-1025. PMID: 25159904
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-80. PMID: 21195524
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26981581
- Sikiric P, et al. "Pentadecapeptide BPC 157 interactions with dopamine and serotonin systems." Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26981581
- Gwyer D, Wragg NM, Wilson SL. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell Tissue Res. 2019;377(2):153-159. PMID: 31320017
- Vukovic T, et al. "Pentadecapeptide BPC 157 and ischemia-reperfusion injury." Ann Med. 2020;52(8):472-487. PMID: 33040779
- Tkalcevic VI, et al. "Enhancement by PL 14736 of restitution and angiogenesis with an antiinflammatory effect in hepatectomy model." Eur J Pharmacol. 2007;570(1-3):85-91. PMID: 17713057
- Sikiric P, et al. "Pentadecapeptide BPC 157 — from laboratory to clinical use." Med Sci Monit. 2010;16(10):BR366-70. PMID: 20885340
- Staresinic M, et al. "Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157." J Orthop Res. 2006;24(5):1109-1117. PMID: 16609979
- Sikiric P, et al. "Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157." Curr Pharm Des. 2013;19(1):76-83. PMID: 22950504
- Sikiric P, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regen Res. 2015;10(11):1735-1736. PMID: 26807095
Related Pages
Concise compound overview with dosing tables
Step-by-step research protocol
Top stacking partner deep-dive
Precise dosing for any vial size
Pre/post protocol lab panels
Monitor active trials
Medical Disclaimer: This article is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. BPC-157 is not approved by the FDA or any regulatory agency for human use. All information is derived from preclinical research and should not be interpreted as clinical guidance. Consult a qualified healthcare professional before considering any research compound. See our full Medical Disclaimer.
